Medeon Biodesign, Inc. (TPEX: 6499)

Market Cap	3.94B
Revenue (ttm)	211.86M
Net Income (ttm)	-810.63M
Shares Out	92.14M
EPS (ttm)	-8.81
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	24,001
Open	43.15
Previous Close	43.05
Day's Range	42.65 - 43.15
52-Week Range	39.45 - 55.00
Beta	0.71
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 1, 2024

About Medeon Biodesign

Medeon Biodesign, Inc. engages in the research and development, manufacturing, and sale of medical devices in Taiwan and the United States. The company focuses on developing devices for minimally invasive surgeries, such as Duett, a vascular graft system; ClickClean, a solution to view throughout laparoscopic surgeries; AbClose to prevent port site herniation caused by improper closure; UroCross, an expander system; PUMA, a solution to treat orthopedic extremity injuries; and Cross-Seal, a large-bore closure device. It is involved in medical de...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 2012
• Employees: 39
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6499

Financial Performance

In 2023, Medeon Biodesign's revenue was 196.26 million, a decrease of -34.21% compared to the previous year's 298.32 million. Losses were -1.20 billion, 177.7% more than in 2022.